NCT04075851

Brief Summary

Thyroid hormone autoantibodies(THAA) in serum can Interfere radioimmunoassay for the determination of free thyroid hormones. Thyroid function test plays a key role in the diagnosis and treatment of autoimmune thyroid disease (AITD), and abnormal examination results in misdiagnosis and mistreatment. At present, the epidemiological results of THAA in AITD are inconsistent, and the pathogenesis has not been clarified. However, there is no relevant research on THAA in China. This project intends to collect AITD patients and healthy people, detecting THAA, at the same time testing thyroid function and thyroid autoantibodies, definiting positive rate of THAA in AITD patients, observing the effect of common therapeutic drugs for AITD on THAA, investigating the rule of THAA influencing thyroid function test results .This project will provide the basis and method for how to effectively avoid THAA interfering with thyroid function test.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
600

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2019

Completed
28 days until next milestone

First Submitted

Initial submission to the registry

August 29, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 3, 2019

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2022

Completed
Last Updated

April 14, 2021

Status Verified

April 1, 2021

Enrollment Period

3 years

First QC Date

August 29, 2019

Last Update Submit

April 12, 2021

Conditions

Keywords

Autoimmune thyroid diseaseThyroid hormone autoantibodiesHashimoto's thyroiditisGrave's disease

Outcome Measures

Primary Outcomes (1)

  • prevalence of thyroid hormone autoantibodies in AITD

    Radioimmuno precipitation test used for thyroid hormone autoantibodies

    measured after 1 year of follow-up

Study Arms (4)

Hashimoto or Grave's disease patients in treatment

Draw 10 ml venous blood

Hashimoto or Grave's disease patients on initial treatment

10 ml of venous blood was extracted every month for three months

Pregnant woman with Hashimoto or Grave's disease

10 ml venous blood was extracted every month to postpartum for 6 months

Healthy crowd

Draw 10 ml venous blood

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with Autoimmune thyroid diseases in endocrine outpatient department of shandong provincial hospital from August 1, 2019 to August 1, 2022

You may qualify if:

  • male or female with Hashimoto thyroiditis or Grave's disease aged for 18 to 65 years old

You may not qualify if:

  • Had a thyroidectomy Had a thyroid fine needle puncture biopsy Autoimmune diseases Take drugs that affect the immune system

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Shandong Province Hospital

Jinan, Shandong, 250021, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum

MeSH Terms

Conditions

Hashimoto Disease

Condition Hierarchy (Ancestors)

Thyroiditis, AutoimmuneThyroiditisThyroid DiseasesEndocrine System DiseasesAutoimmune DiseasesImmune System Diseases

Study Officials

  • Haiqing Zhang

    shandong province hospital

    STUDY CHAIR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 29, 2019

First Posted

September 3, 2019

Study Start

August 1, 2019

Primary Completion

August 1, 2022

Study Completion

August 1, 2022

Last Updated

April 14, 2021

Record last verified: 2021-04

Locations